Deep Bio, an AI-based medical solutions provider, said Tuesday that it has appointed Lee Soo-hyun, a former accountant at Samil PwC with experience in many IPOs, as its new chief finance officer.

New CFO Lee will oversee the investment, technology special listing, and growth strategy at Deep Bio. The company, which specializes in data-driven medicine, plans to accelerate preparations for its IPO scheduled for 2025.

Lee is a certified public accountant specializing in finance with 17 years of experience in IPO, M&A, and business planning at the TS-FAS headquarters of Samil PwC and the IPO team at Samsung Securities. He has also been preparing for investment, M&A acquisitions, and IPOs as a Megazone Digital strategic planning team member. He has experience leading IPOs as the CFO of semiconductor equipment company HPSP.

"The addition of an IPO strategist and accountant will bring a new wind of change to the company," Deep Bio CEO Kim Sun-woo said. "We will use this to take a step forward as a global AI-based healthcare company for cancer diagnosis."